Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on July 10, 2020 in Ovarian Cancer
The approval of 3 PARP inhibitors has made it feasible to personalize therapy for patients with ovarian cancer based on their mutation status as well as other factors, including the treatment setting.
Web Exclusives published on July 10, 2020 in Ovarian Cancer
The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients.
Web Exclusives published on June 22, 2020 in FDA Updates, Lung Cancer
On June 15, 2020, the FDA accelerated the approval of lurbinectedin (Zepzelca; Jazz Pharma/Pharma Mar), an intravenous alkylating drug, for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy. The FDA granted lurbinectedin an orphan drug designation for this indication.
Web Exclusives published on June 22, 2020 in FDA Updates
On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer.
Web Exclusives published on June 8, 2020 in FDA Updates, Lung Cancer
On May 29, 2020, the FDA approved ramucirumab (Cyramza; Eli Lilly) in combination with erlotinib (Tarceva) for first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. Ramucirumab was previously approved for several types of cancer, including, in combination with docetaxel, for metastatic NSCLC, after platinum-based chemotherapy.
Web Exclusives published on June 8, 2020 in Ovarian Cancer
Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy.
Web Exclusives published on June 8, 2020 in Ovarian Cancer
In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies.
Web Exclusives published on June 8, 2020 in Ovarian Cancer
The Centers for Medicare & Medicaid Services (CMS) has announced an expansion of coverage for telehealth services for Medicare beneficiaries. To qualify, 2-way real-time interactive communication between providers and patients using both audio and video technology is required.
Web Exclusives published on June 8, 2020 in Ovarian Cancer
Remote patient monitoring, in which digital technologies are used to detect changes in vital signs or symptoms, may offer a convenient way to signal the need for a change in management, thereby potentially improving outcomes.
Web Exclusives published on June 8, 2020 in Ovarian Cancer
According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years.
Page 2 of 25
Results 11 - 20 of 247